LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Part of paid clinical trials in Tucson, Arizona.
- Sponsor
- OrphAI Therapeutics
- Study ID
- NCT05798923
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Placebo — DRUGMatching placebo administered via dry powder inhalation
- LAM-001 — DRUGLAM-001 administered via dry powder inhaler
Study Details
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).
Key Dates
- First listed
- Apr 5, 2023
- Start date
- Aug 30, 2023
- Status verified
- Jul 2026
- Primary completion
- Jul 16, 2027
- Completion
- Aug 30, 2028
Study Design
- Enrollment
- 85 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Matched PlaceboPlacebo (1 or 2 oral inhalations) administered once daily via a Dry Powder Inhaler (DPI)
- Active Comparator: LAM-001 - High DoseLAM-001 (2, 100 mcg oral inhalations) once daily via a Dry Powder Inhaler (DPI)
- Active Comparator: LAM-001 - Low DoseLAM-001 (1, 100 mcg oral inhalation) once daily via a Dry Powder Inhaler (DPI)
Primary Outcome Measure
To determine the change in PVR at 24 weeks [ Time Frame: 24 weeks ]
Central Contacts
- OrphAI Therapeutics2034332737
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Arizona | Tucson | Arizona | 85748 | OrphAI Therapeutics Franz Rischard, DO (PRINCIPAL_INVESTIGATOR) |
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | OrphAI Therapeutics Phillip Joseph, MD (PRINCIPAL_INVESTIGATOR) |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | OrphAI Therapeutics Benjamin Stump, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Tucson, AZ
Related Studies
- DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Recruiting · United Therapeutics · Birmingham, Alabama
- Pulmonary Hypertension Biorepository and RegistryRecruiting · University of Kansas Medical Center · Kansas City, Kansas
- Ventilator Pressure and Optimization of Compliance and HemodynamicsRecruiting · University of Alabama at Birmingham · Birmingham, Alabama